Theratyping of the ultra-rare CFTR variant p.Phe1078Ser: functional correction by CFTR modulators in human bronchial epithelial CFBE cells

Background CFTR c.3233 T>C (p.(Phe1078Ser); F1078S) is an ultra-rare missense variant for which clinical and functional data are very limited. As theratyping is an important experimental component of precision theranostics in cystic fibrosis (CF), we investigated the molecular and functional consequences of F1078S and its responsiveness to CFTR modulators. Methods F1078S-CFTR was transiently expressed in human bronchial epithelial CFBE41o − cells using a GFP-tagged CFTR construct. CFTR protein processing and biosynthesis were assessed by Western blotting, while channel function was evaluated by Ussing chamber recordings. The effects of elexacaftor and vanzacaftor, each combined with tezacaftor were investigated. F1078 was mapped on the three-dimensional (3D) structure of human CFTR. Results F1078 is located at the ICL1/ICL4 interface, near the “pocket” left vacant by F508 in patients with F508del (ICL4/NBD1 interface). F1078S-CFTR exhibited defective protein processing, as evidenced by the absence of the mature C-band, and showed no detectable CFTR channel function. Treatment of F1078S-expressing CFBE41o − cells with elexacaftor/tezacaftor or vanzacaftor/tezacaftor restored CFTR protein processing and rescued channel function. Conclusion F1078S located in a critical region for folding and assembly, exhibits a CFTR processing/trafficking defect consistent with a class II molecular phenotype, together with impaired channel function. Both defects were rescued by elexacaftor/tezacaftor and vanzacaftor/tezacaftor, providing functional evidence of CFTR modulator responsiveness for this ultra-rare variant. These findings highlight the potential of theratyping to inform individualized therapeutic strategies for patients carrying rare CFTR variants.

Authors

Institutions

Publication Details

Journal
Frontiers in Pharmacology
Published
2026-11-19
DOI
https://doi.org/10.3389/fphar.2026.2007119
Primary Topic
Cystic Fibrosis Research Advances
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Theratyping of the ultra-rare CFTR variant p.Phe1078Ser: functional correction by CFTR modulators in human bronchial epithelial CFBE cells

Hugues Abriel, Louise Damy, C. Barrault, Matthieu Régnacq et al.
Frontiers in Pharmacology
Cystic Fibrosis Research Advances
article

Theratyping of the ultra-rare CFTR variant p.Phe1078Ser: functional correction by CFTR modulators in human bronchial epithelial CFBE cells

Hugues Abriel, Louise Damy, C. Barrault, Matthieu Régnacq, Frédéric Becq, Sandra Mirval, Nada El Makhzen, Isabelle Callebaut, Mael Estivalezes
article en

Abstract

Background CFTR c.3233 T>C (p.(Phe1078Ser); F1078S) is an ultra-rare missense variant for which clinical and functional data are very limited. As theratyping is an important experimental component of precision theranostics in cystic fibrosis (CF), we investigated the molecular and functional consequences of F1078S and its responsiveness to CFTR modulators. Methods F1078S-CFTR was transiently expressed in human bronchial epithelial CFBE41o − cells using a GFP-tagged CFTR construct. CFTR protein processing and biosynthesis were assessed by Western blotting, while channel function was evaluated by Ussing chamber recordings. The effects of elexacaftor and vanzacaftor, each combined with tezacaftor were investigated. F1078 was mapped on the three-dimensional (3D) structure of human CFTR. Results F1078 is located at the ICL1/ICL4 interface, near the “pocket” left vacant by F508 in patients with F508del (ICL4/NBD1 interface). F1078S-CFTR exhibited defective protein processing, as evidenced by the absence of the mature C-band, and showed no detectable CFTR channel function. Treatment of F1078S-expressing CFBE41o − cells with elexacaftor/tezacaftor or vanzacaftor/tezacaftor restored CFTR protein processing and rescued channel function. Conclusion F1078S located in a critical region for folding and assembly, exhibits a CFTR processing/trafficking defect consistent with a class II molecular phenotype, together with impaired channel function. Both defects were rescued by elexacaftor/tezacaftor and vanzacaftor/tezacaftor, providing functional evidence of CFTR modulator responsiveness for this ultra-rare variant. These findings highlight the potential of theratyping to inform individualized therapeutic strategies for patients carrying rare CFTR variants.

Frontiers in PharmacologyVol. 17
University of Bern (CH), Centre National de la Recherche Scientifique (FR), Université de Poitiers (FR), Sorbonne Université (FR), Institut de minéralogie, de physique des matériaux et de cosmochimie (FR)
Cystic Fibrosis Research Advances
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon